Kobayashi N, Murayama Y, Yuki I, Ishibashi T, Ebara M, Arakawa H, Irie K, Takao H, Kajiwara I, Nishimura K, Karagiozov K, Urashima M
From the Department of Neurosurgery (N.K., Y.M., I.Y., T.I., M.E., H.A., K.I., H.T., I.K., K.N., K.K.).
From the Department of Neurosurgery (N.K., Y.M., I.Y., T.I., M.E., H.A., K.I., H.T., I.K., K.N., K.K.)
AJNR Am J Neuroradiol. 2014 Jul;35(7):1371-5. doi: 10.3174/ajnr.A3873. Epub 2014 Mar 7.
The natural history and therapeutic management of dissecting vertebrobasilar aneurysms without ischemic or hemorrhagic stroke (nonstroke dissecting vertebrobasilar aneurysms) are not well-established. We conservatively followed patients with nonstroke dissecting vertebrobasilar aneurysms and evaluated the factors related to clinical and morphologic deterioration.
One hundred thirteen patients were enrolled and divided by clinical presentation at diagnosis: asymptomatic (group 1, n = 52), pain only (group 2, n = 56), and mass effect (group 3, n = 5). Patients were conservatively managed without intervention and antithrombotic therapy. Clinical outcomes and morphologic changes were analyzed.
A total of 113 patients who were diagnosed with nonstroke dissecting vertebrobasilar aneurysm had a mean follow-up of 2.9 years (range, 27 days to 8 years). Throughout that period, 1 patient in group 1 (1.9%) and 1 patient in group 2 (1.8%) showed clinical deterioration due to mass effect, and 1 patient in group 3 (20%) developed ischemic stroke followed by subarachnoid hemorrhage. Most patients (97.3%) were clinically unchanged. Three patients who had clinical deterioration showed aneurysm enlargement (P < .001). Aneurysms remained morphologically unchanged in 91 patients (80.5%). Aneurysm enlargement was seen in 5 patients (4.4%); risk of enlargement was significantly associated with either maximum diameter (hazard ratio = 1.30; 95% CI, 1.11-11.52; P = .001) or aneurysm ≥10 mm (hazard ratio = 18.0; 95% CI, 1.95-167; P = .011).
The natural course of these lesions suggests that acute intervention is not always required and close follow-up without antithrombotic therapy is reasonable. Patients with symptoms due to mass effect or aneurysms of >10 mm may require treatment.
无缺血性或出血性卒中的椎动脉夹层动脉瘤(非卒中椎动脉夹层动脉瘤)的自然病程及治疗管理尚未完全明确。我们对非卒中椎动脉夹层动脉瘤患者进行了保守随访,并评估了与临床及形态学恶化相关的因素。
纳入113例患者,根据诊断时的临床表现进行分组:无症状(第1组,n = 52)、仅有疼痛(第2组,n = 56)和有占位效应(第3组,n = 5)。患者接受保守治疗,未进行干预及抗血栓治疗。分析临床结局及形态学变化。
113例诊断为非卒中椎动脉夹层动脉瘤的患者平均随访2.9年(范围:27天至8年)。在此期间,第1组1例患者(1.9%)和第2组1例患者(1.8%)因占位效应出现临床恶化,第3组1例患者(20%)发生缺血性卒中后继发蛛网膜下腔出血。大多数患者(97.3%)临床情况未变。3例临床恶化的患者出现动脉瘤增大(P <.001)。91例患者(80.5%)的动脉瘤形态保持不变。5例患者(4.4%)出现动脉瘤增大;增大风险与最大直径(风险比 = 1.30;95%可信区间,1.11 - 11.52;P =.001)或动脉瘤≥10 mm(风险比 = 18.0;95%可信区间,1.95 - 167;P =.011)显著相关。
这些病变的自然病程提示并非总是需要急性干预,不进行抗血栓治疗而密切随访是合理的。有占位效应症状或动脉瘤直径>10 mm的患者可能需要治疗。